This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
ETFs to Watch as Biden Heads to White House
by Sweta Killa
The new administration is expected to bring a wave of policy shifts and roll back some of the regulations implemented by the former president Donald Trump's administration.
3 Reasons to Bet on Healthcare ETFs
by Sanghamitra Saha
The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.
Sector ETFs to Win/Lose If Biden Wins Elections
by Sanghamitra Saha
Since Democratic candidate Biden has high chances of winning the U.S. election this year, these sector ETFs are likely to gain/lose.
S&P 500 Near Record Close: 3 Winning Sectors & ETFs
by Sanghamitra Saha
S&P 500 got charged up on Aug 12 on vaccine and further stimulus hopes as well as better-than-feared second-quarter earnings.
10% Correction in the Cards? Play ETFs With Inherent Strength
by Sanghamitra Saha
Michael Wilson, chief U.S. equity strategist at Morgan Stanley believe that ???the most likely outcome remains a 10% correction in the broader index." However, we believe stocks and ETFs with solid fundamentals should soar higher.
Top-Performing ETFs of Last Week
by Sanghamitra Saha
Last week was moderately upbeat for Wall Street with vaccine hopes boosting risk-on sentiments.
Blue Wave to Hit America? Sector ETFs to Win or Lose
by Sanghamitra Saha
Chances are rising that the blue wave of Democrats will take control over the House and Senate in November.
Sector ETFs to Win or Lose if Blue Wave Sweeps U.S. Election
by Sanghamitra Saha
Chances are rising that the blue wave of Democrats will take control over the House and Senate in November.
Biden Gains Popularity, Demands Tax Hike: ETFs at Risks
by Sanghamitra Saha
Democratic presidential candidate Joe Biden now has 55% chance of winning the November election, according to online market and political event forecaster PredictIt.
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners
by Sanghamitra Saha
Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.